首页> 外文期刊>Drug Design, Development and Therapy >Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on “Unification of Medicines and Excipients”
【24h】

Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on “Unification of Medicines and Excipients”

机译:基于“药物和赋形剂的统一”,含有柚皮蛋白和薏ing液和薏ix液的纳米结构脂质载体的制剂和评价。

获取原文
           

摘要

Background: “Unification of medicines and excipients” is the special principle which means fatty oil with pharmacodynamic activity derived from traditional Chinese medicine are taken as liquid lipids in perparation for dual-drug delivery, which improve the treatment effect and reduce unnecessary excipients. Purpose: The aim of this study was to prepare a nanostructured lipid carrier (NLC) with naringin (NG) containing coix seed oil (CSO) as liquid lipid based on the theory (NCNLC) in order to achieve synergistic antitumor activity against hepatocellular carcinoma. Methods: We developed NCNLCs using ultrasonic melt-emulsification method. The antitumor effect in vivo/in vitro and drug release ability were compared to NLC prepared with conventional liquid lipids: neodecanoate triglycerides (NDNLC) and oleic acid (NONLC). Results: Transmission electron microscopy showed that NCNLCs had a well-defined spherical shape, small size, and narrow polydispersity index. Importantly, the release of drugs from NDNLCs and NONLCs was slower than NCNLCs. In the cell study, the result showed a significantly greater antiproliferative effect towards HepG2 cells, and?the half-maximal inhibitory concentration of NCNLCs was 3.24-fold, 1.70-fold and 1.52-fold lower to that of free drug, NDNLCs and NONLCs, respectively. Moreover, NCNLCs significantly induced HepG2 cells apoptosis by being 2.12-fold and 9.28-fold higher to that of NDNLCs and NONLCs, respectively. In the study of antitumor efficacy in vivo, the synergistic effect of NCNLCs formulation showed markedly enhanced antitumor efficacy in a xenograft model of liver cancer. Conclusion: The advantages of “unification of medicines and excipients” in formulation characters, drug release and synergistic antitumor effect provide a new idea for the application of the fatty oil of traditional Chinese medicine in the nano-drug delivery for cancer therapy.
机译:背景:“药物和赋形剂的统一”是特殊原理,意为脂肪油与来自中药衍生的药物动力学活性的脂肪油作为液体脂质,以促进双药物递送,这改善了治疗效果并减少了不必要的赋形剂。目的:本研究的目的是制备含有凝聚蛋白(Ng)的纳米结构脂质载体(NLC),作为基于理论(NCNLC)的液体脂质,以实现对肝细胞癌的协同抗肿瘤活性。方法:采用超声波熔融乳化方法开发了NCNLCS。将体内/体外和药物释放能力的抗肿瘤效应与用常规液体脂质制备的NLC进行比较:新癸酸酯甘油三酯(NDNLC)和油酸(NONLC)。结果:透射电子显微镜显示NCNLC具有明确定义的球形形状,小尺寸和窄多分散指数。重要的是,来自NDNLC和NONLCS的药物的释放比NCNLC慢。在细胞研究中,结果对HepG2细胞显示出显着更大的抗增殖作用,并且α的NCNLC的半最大抑制浓度为3.24倍,1.70倍,1.52倍,下降至1.52倍,下降至1.52倍,分别。此外,NCNLCs分别显着诱导HepG2细胞凋亡,分别为2.12倍和9.28倍,分别为NDNLC和NONLCS的凋亡。在体内抗肿瘤功效的研究中,NCNLCS制剂的协同作用显示在肝癌的异种移植模型中显着增强了抗肿瘤功效。结论:制剂特征“统一”,药物释放和协同抗肿瘤效应的“药物和赋形剂统一”的优势为癌症治疗纳米药物递送中的中药脂肪油应用了一种新的想法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号